All In Biotech

Drug Trial Radar · NCT07010302

Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD

A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab and Eculizumab To Prevent Relapses in Neuromyelitis Optica Spectrum Disorder

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 540 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

540

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Jan 2030

Study completion May 2030

Sponsor

Lead sponsor
Massachusetts General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Patient-Centered Outcomes Research Institute; Charite University, Berlin, Germany; The Sumaira Foundation
First posted
Jun 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune condition that mainly affects the eyes and spinal cord, causing serious symptoms such as vision loss, paralysis, and severe pain. This trial compares the effectiveness and safety of five medications commonly used to prevent NMOSD relapses: rituximab, ravulizumab, inebilizumab, satralizumab, and eculizumab. In this study, 160 adults with NMOSD who test positive for a specific antibody (AQP4-IgG) will participate. They will be randomly assigned to receive either rituximab or one of the four other FDA-approved medications. The main goal is to find out which treatment best prevents relapses and has fewer serious side effects. The trial will also measure disability, patient satisfaction, quality of life, and biomarkers that help track disease activity. Participants will have regular assessments, including medical exams, surveys, and tests for vision, walking ability, and brain function. They will report any side effects or health issues experienced during the study. The trial will last from one to four years for each participant. This research aims to help patients and doctors make better-informed treatment decisions by providing clear evidence about the best available therapies for NMOSD.

Conditions

  • NMOSD

Interventions

  • Rituximab (R)Drug

    1000 mg at weeks 0 and 2 followed by 1000 mg every 6 months

  • Eculizumab (Soliris®)Drug

    900 mg weekly for 4 weeks, followed by 1200 mg every 2 weeks

  • RavulizumabDrug

    * 40 to \< 60 kg: 2400 mg * 60 to \< 100 kg: 2700 mg * 100 kg: 3000 mg as an induction dose, followed by * 40 to \< 60 kg: 3000 mg * 60 to \< 100 kg: 3300 mg * 100 kg: 3600 mg Every 8 weeks starting 15 days after loading dose

  • SatralizumabDrug

    120 mg at Weeks 0, 2, 4, followed by 120 mg every 4 weeks

  • InebilizumabDrug

    300 mg on Day 1 and Day 15, followed by 300 mg every 6 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to adjudicated safety or tolerability failureTime frame: From date of randomization until the date of first adjudicated safety or tolerability failure or adjudicated relapse, whichever comes first, assessed up to 48 months
  2. Time to adjudicated relapseTime frame: From date of randomization until the date of adjudicated relapse or first treatment discontinuation, whichever comes first, assessed up to 48 months

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.